Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00088959 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

NIH

Sponsor class

Conditions

Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: erlotinib hydrochloride
DRUG: celecoxib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)